Adenovirus de-targeting from the liver

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 523-531

  Di Paolo, N C ^a   Shayakhmetov, D M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; Gene transfer; Liver; Virotherapy; Virus host interaction

Indexed keywords

ADENOVIRUS VECTOR; CD51 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MACROGOL; MEMBRANE COFACTOR PROTEIN; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; PROTEOHEPARAN SULFATE; STRUCTURAL PROTEIN; VIRUS FIBER PROTEIN; VIRUS PROTEIN;

CHEMICAL MODIFICATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; HEXON; HUMAN; HUMAN ADENOVIRUS 5; KUPFFER CELL; LIVER CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS FIBER; VIRUS MUTATION;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIVER; MODELS, BIOLOGICAL; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 70349906857     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Ruuskanen O, Meurman O, Akusjarvi G: Adenoviruses. In: Clinical Virology. Richman DD, Whitley RJ, Hayden FG (Eds), ASM Press, Herndon, VA, USA (2002):515-534.
2. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies WA, Hogg JC: Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis (1992) 146(1): 177-184.
3. Garnett CT, Erdman D, Xu W, Gooding LR: Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol (2002) 76(21):10608-10616. (Pubitemid 35176177)
4. Garnett CT, Talekar G, Mahr JA, Huang W, Zhang Y, Ornelles DA, Gooding LR: Latent species C adenoviruses in human tonsil tissues. J Virol (2009) 83(6):2417-2428.
5. Benyesh-Melnick M, Rosenberg HS: Isolation of adenovirus type 7 from fatal case of pneumonia + disseminated disease. J Pediatr (1964) 64:83-87.
6. Wigger HJ, Blanc WA: Fatal hepatic and bronchial necrosis in adenovirus infection with thymic alymphoplasia. N Engl J Med (1966) 275(16):870-874.
7. Zuckerma AJ, Alwen J, Fulton F: Adenovirus infection of human embryo liver cells. Nature (1967) 214(5088):606-608.
8. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther (1990) 1(3):241-256. (Pubitemid 120034730)
9. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson SS, Stratfordperricaudet LD, Perricaudet M, Pavirani A et al: Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet (1992) 1(5):372-378.
10. Li QT, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL: Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther (1993) 4(4):403-409. (Pubitemid 24308308)
11. Morsy MA, Alford EL, Bett A, Graham FL, Caskey CT: Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest (1993) 92(3):1580-1586.
12. Smith TA, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M: Adenovirus mediated expression of therapeutic plasma levels of human Factor IX in mice. Nat Genet (1993) 5(4):397-402. (Pubitemid 23351313)
13. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL: Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA (1993) 90(24):11548-11552.
14. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang BL, Bellinger D, Finegold M, Thompson AR, Read M et al: In vivo hepatic gene therapy: Complete albeit transient correction of Factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA (1994) 91(6):2353-2357.
15. Huard J, Lochmüller H, Acsadi G, Jani A, Massie B, Karpati G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther (1995) 2(2):107-115.
16. 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73(2):309-319. •• Presents a detailed analysis of the critical role of cellular integrins in Ad internalization into the cell.
17. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320-1323. •• Describes the discovery of the human species CAR.
18. Tomko RP, Xu R, Philipson L: HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA (1997) 94(7):3352-3356. •• Describes the discovery of human CAR and its mouse homolog, as well as the expression profiles of the receptors in different tissues.
19. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ: The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol (1998) 72(10):7909-7915.
20. Nemerow GR: Cell receptors involved in adenovirus entry. Virology (2000) 274(1):1-4.
21. v integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev (1999) 63(3):725-734.
22. 99mTc- labeled adenovirus knob (serotype 5). Gene Ther (1998) 5(6):798-808. • Demonstrated that the recombinant, purified fiber knob domain of Ad5 was efficiently trapped in the liver following intravenous administration of the virus.
23. v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther (1999) 6(9):1520-1535. • Provides evidence that CAR expression does not correlate with Ad-mediated tissue transduction in mice following intravenous virus administration.
24. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, Wilson DR: Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther (1999) 6(4):367-372.
25. Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 81(Pt 11):2605-2609.
26. Johnson M, Huyn S, Burton J, Sato M, Wu L: Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Human Gene Ther (2006) 17(12):1262-1269. (Pubitemid 44975142)
27. Alemany R, Curiel DT: CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther (2001) 8(17):1347-1353. (Pubitemid 32834304)
28. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T: Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther (2003) 8(5):813-821. (Pubitemid 37527457)
29. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 3(1):28-35. (Pubitemid 32509802)
30. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 8(1): 37-44. (Pubitemid 27075341)
31. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol (1997) 71(11):8798-8807. (Pubitemid 27446464)
32. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG: Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol (1997) 71(1):624-629. (Pubitemid 26412334)
33. Kuzmin AI, Finegold MJ, Eisensmith RC: Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther (1997) 4(4):309-316.
34. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A: Evaluation of biodistribution and safety of adenovirus vectors containing B-group fibers after intravenous injection into baboons. Hum Gene Ther (2005) 16(6):664-677.
35. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P: Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther (2004) 15(1):35-46. (Pubitemid 38147187)
36. Brunetti-Pierri N, Palmer DJ, Mane V, Finegold M, Beaudet AL, Ng P: Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther (2005) 12(1):99-106.
37. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, Nicklin SA, Stevenson SC, Baker AH: Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther (2004) 10(2):344-354.
38. Hodges BL, Taylor KM, Chu Q, Scull SE, Serriello RG, Anderson SC, Wang F, Scheule RK: Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver. Mol Ther (2005) 12(6):1043-1051.
39. Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA: A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood (2003) 102(7):2403-2411.
40. Stone D, Ni SH, Li ZY, Gaggar A, DiPaolo N, Feng QH, Sandig V, Lieber A: Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol (2005) 79(8):5090-5104. (Pubitemid 40464259)
41. Stone D, Liu Y, Li ZY, Tuve S, Strauss R, Lieber A: Comparison of blood interaction and organ biodistribution for adenoviruses from species B, C, E and F. Mol Ther (2007) 15(12):2146-2153.
42. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S: Development of adenovirus serotype 35 as a gene transfer vector. Virology (2003) 311(2): 384-393. (Pubitemid 36808779)
43. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK: Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 386(1):44-54.
44. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, Nemerow GR, Kaleko M, Stevenson SC: Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther (2003) 14(8):777-787. •• Describes the construction and properties of a fiber shaft-mutated Ad, AdS*, which exhibited reduced liver transduction following intravenous virus administration. (Pubitemid 36623514)
45. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M, King L, Mech C, Dinges L, Iverson WO, Sherer AD et al: Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther (2003) 14(17):1595-1604. (Pubitemid 37452870)
46. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G: Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol (2001) 75(18):8772-8780.
47. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G: Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology (2000) 268(2):382-390. (Pubitemid 30159987)
48. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, Von Seggern DJ, Work LM, McVey JH, Nicklin SA, Baker AH: Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther (2007) 15(4):741-749.
49. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R: Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol (2006) 87(Pt 9):2487-2495.
50. Di Paolo NC, Kalyuzhniy O, Shayakhmetov DM: Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J Virol (2007) 81(22):12249-12259.
51. Breidenbach M, Rein DT, Wang M, Nettelbeck DM, Hemminki A, Ulasov I, Rivera AR, Everts M, Alvarez RD, Douglas JT, Curiel DT: Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther (2004) 15(5):509-518.
52. v integrin-binding ablation. J Virol (2003) 77(24):13062-13072.
53. Denby L, Work LM, Graham D, Hsu C, Von Seggern DJ, Nicklin SA, Baker AH: Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum Gene Ther (2004) 15(11):1054-1064.
54. Shayakhmetov DM, Li ZY, Ni S, Lieber A: Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 62(4):1063-1068.
55. Shayakhmetov DM, Li ZY, Ni S, Lieber A: Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 78(10):5368-5381. • Presents data demonstrating that Ad particles are trapped in the liver independently of hepatocyte transduction following intravenous virus administration.
56. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H: Ablating CAR and integrins binding and fiber shaft exchange in adenovirus vectors reduces tissue transduction and toxicity after systemic administration. J Gene Med (2006) 8(3):404.
57. Saban SD, Nepomuceno RR, Gritton LD, Nemerow GR, Stewart PL: CryoEM structure at 9 angstrom resolution of an adenovirus vector targeted to hematopoietic cells. J Mol Biol (2005) 349(3):526-537.
58. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ et al: Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 78(6):2666-2673. (Pubitemid 38314325)
59. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS et al: Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 174(11): 7179-7185. (Pubitemid 40705685)
60. Benihoud K, Vigant, F, Descamps D, Esselin S, Jullienne B, Challuau D, Connault E, Opolon P, Vigne E, Perricaudet M: Reduction of adenovirus tropism to the liver by modification of hexon protein. International Adenovirus Meeting, Zurich, Switzerland (2006) 8:Abs E11-E10.
61. Shayakhmetov DM, Gaggar A, Ni SH, Li ZY, Lieber A: Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 79(12):7478-7491. •• Provided the first evidence, as well as a model, for the blood factor-assisted entry of Ad into hepatocytes following intravenous virus administration.
62. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, Kemball-Cook G, Ni S, Lieber A, McVey JH, Nicklin SA et al: Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 108(8):2554-2561.
63. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL, Shayakhmetov DM: Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA (2008) 105(14):5483-5488. •• Provided evidence, along with reference [64], for the critical role of Ad5 hexon in binding blood coagulation Factor X, leading to hepatocyte transduction in mice.
64. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J et al: Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 132(3):397-409. •• Provided evidence, along with reference [63], for the critical role of Ad5 hexon in binding blood coagulation Factor X, leading to hepatocyte transduction in mice. (Pubitemid 351200513)
65. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH et al: Identification of coagulation Factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 114(5):965-971.
66. Waddington SN, Parker AL, Havenga M, Nicklin SA, Buckley SM, McVey JH, Baker AH: Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol (2007) 81(17):9568-9571. (Pubitemid 47311502)
67. Chillón M, Lee JH, Fasbender A, Welsh MJ: Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther (1998) 5(7): 995-1002. (Pubitemid 28371917)
68. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther (1999) 10(8):1349-1358. • The first study to demonstrate the possibility of shielding Ad particles from blood proteins (ie, neutralizing antibodies) in vivo using the chemical modification of Ad capsid with polymetic compounds.
69. Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, Aukerman SL: Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther (2000) 11(1):191-204.
70. Kreppel F, Gackowski J, Schmidt E, Kochanek S: Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther (2005) 12(1):107-117.
71. Croyle MA, Chirmule N, Zhang Y, Wilson JM: PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther (2002) 13(15):1887-1900.
72. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW: Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther (2004) 11(16):1256-1263. (Pubitemid 39173432)
73. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA: Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 18(9):837-848.
74. Di Paolo NC, van Rooijen N, Shayakhmetov DM: Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther (2009) 17(4): 675-684. •• Provides experimental confirmation to the hypothesis that molecular mechanisms responsible for the trapping of blood-borne Ad in the liver operate in a redundant, synergistic and orderly manner.
75. Ye XH, Jerebtsova M, Ray PE: Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther (2000) 11(4):621-627.
76. Shashkova EV, Doronin K, Senac JS, Barry MA: Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 68(14):5896-5904. •• Demonstrated that overcoming the redundancy of the Ad trapping mechanisms by the liver leads to significantly improved availability of the virus for transduction of extrahepatic tissues.
77. Lievens J, Snoeys J, Vekemans K, Van Linthout S, de Zanger R, Collen D, Wisse E, De Geest B: The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther (2004) 11(20):1523-1531. (Pubitemid 39359460)
78. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B: The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transfer. Gene Ther (2008) 15(17):1193-1199.
79. Seregin SS, Aldhamen YA, Appledorn DM, Schuldt NJ, McBride AJ, Bujold M, Godbehere SS, Amalfitano A: CR1/2 is an important suppressor of adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther (2009):doi:10.1038/gt.2009.77.
80. Appledorn DM, McBride A, Seregin S, Scott JM, Schuldt N, Kiang A, Godbehere S, Amalfitano A: Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther (2008) 15(24): 1606-1617.
81. Cotter MJ, Zaiss AK, Muruve DA: Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol (2005) 79(23):14622-14631.
82. Xu Z, Tian J, Smith JS, Byrnes AP: Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 82(23):11705-11713.
83. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD et al: Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther (2006) 14(1):118-128. (Pubitemid 44191831)
84. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, Subr V, Ulbrich K, Gilbert RJ, Fisher KD, Finberg RW et al: Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 113(9):1909-1918.
85. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C, Mennechet F, Schoehn G, Lortat-Jacob H, Dreja H, Ibanes S et al: The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog (2009) 5(1):e1000277.
86. Lenaerts L, McVey JH, Baker AH, Denby L, Nicklin S, Verbeken E, Naesens L: Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. J Gene Med (2009) 11(2):119-127.
87. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR: Minimal hepatic toxicity of Onyx-015: Spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther (2007) 14(2):139-150. • Presents clinical trial data demonstrating low-level hepatotoxicity of an oncolytic Ad following intravascular administration in patients with cancer. (Pubitemid 46106958)